BVXV | BiondVax Pharmaceuticals Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.3100 - 1.3600
52 Week Range	0.6300 - 11.49
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	22,668
Average Volume	38,939
Shares Outstanding	3,651,930
Market Cap	4,966,625
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-05-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.58
Forward P/E Ratio	N/A
EPS	-2.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	33
Country	Israel
Website	BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

BVXV's peers: CANF, XTLB

*Chart delayed

Analyzing fundamentals for BVXV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BVXV Fundamentals page.

Watching at BVXV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on BVXV Technicals page.